09 June 2011 Oxford University Press (OUP)
Analysis Finds Mortality From All Causes Higher Among Hepatitis C-Infected
Although liver-related mortality among those infected with hepatitis C is well-documented, little is known about deaths in these patients that are not related to liver problems. A new study published in Clinical Infectious Diseases and now available online sought to determine mortality from all causes, including liver- and non-liver related deaths among hepatitis C patients in the general U.S. population. The analysis found mortality from all causes to be higher in these patients.
An estimated 4 million adults in the U.S. tested positive for hepatitis C, according to the Third National Health and Nutritional Examination Survey, a large, nationally representative survey, conducted from 1988 to 1994. During a follow-up period of almost 15 years, 614 deaths occurred among 9,378 adults assessed in this study.
Among 203 people with chronic hepatitis C infection, 44 died, nine from liver-related causes. The remaining 35 deaths were due to HIV infection, diabetes, heart disease, cancer, and other causes. Compared to individuals who tested negative for hepatitis C, patients with chronic hepatitis C infection had more than a two-fold risk of dying from both liver- and non-liver related causes.
“This should reinforce the importance of preventive measures, particularly among individuals at-risk for acquiring the disease, as well as early diagnosis, and improving access to care for those already infected, even in the absence of liver disease,” said the lead author of the study, Dr. Samer El-Kamary, of the University of Maryland School of Medicine in Baltimore. “While a hepatitis C infection itself may not be the cause of death, patients with the disease may be at a higher risk of dying due to other high-risk behaviors that may have also caused the infection. Furthermore, it is possible that other comorbidities like diabetes and cardiovascular disease could get worse if there is an underlying hepatitis C infection.”
Dr. El-Kamary added, “Given the low cost for hepatitis C tests, perhaps it would be advisable to consider more liberal early screening of patients if there is any suspicion of infection so they can be referred for treatment as early as possible.”
http://www.oxfordjournals.org/our_journals/cid/cir306.pdf
Of Interest;
What’s Next for Hepatitis C
Without question, the recent approvals of telaprevir (Vertex) and boceprevir (Merck) for the treatment of hepatitis C infection marks the beginning of a new time for hepatitis C. This advance is genuinely significant, and after all the me-too drugs and incremental gains we’ve all grown used to reading about, it’s exciting to see two medications that are making a real difference for a large portion of the 170 million people worldwide infected with the virus. The drugs are protease inhibitors; they work by blocking the enzyme that enables the virus to survive in a host. And yet, much more remains. Here’s a look at what is still needed in the realm of hepatitis C care:
No comments:
Post a Comment